Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis

Tina Slusher, Daniel Gbadero, Cynthia Howard, Laura Lewison, Brett Giroir, Luis Toro, Daniel Levin, Elizabeth Holt, George H. Mccracken

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective. To determine the effect of moderate dose dexamethasone administered before antibiotics on the outcome of African children with sepsis. Methods. The design was a randomized, double blinded, placebo- controlled trial of dexamethasone (0.2 mg/kg) vs. placebo given intravenously before antibiotic therapy. Patients were recruited from the patient populations at two missionary hospitals. Primary outcome variables were determined before analysis of data. Results. Seventy-two children with sepsis were enrolled in the study. Treatment with dexamethasone was not associated with improved outcome for any six outcome variables: survival to discharge (83%, dexamethasone group; 89%, placebo group); hemodynamic stability at 48 h (33%, dexamethasone group; 49%, placebo group); median length of hospital stay (11 days, dexamethasone group; 11 days, placebo group); normal at discharge (90%, dexamethasone group; 75%, placebo group); normal at follow- up (90%, dexamethasone group; 72%, placebo group); and afebrile at 48 to 72 h(61%, dexamethasone group; 44%, placebo group). Conclusions. These data indicate that a moderate dose of dexamethasone given before antibiotic therapy did not improve outcome in the pediatric patients with sepsis whom we studied.

Original languageEnglish (US)
Pages (from-to)579-583
Number of pages5
JournalPediatric Infectious Disease Journal
Volume15
Issue number7
DOIs
StatePublished - Jul 1 1996

Fingerprint

Dexamethasone
Sepsis
Placebos
Anti-Bacterial Agents
Length of Stay
Therapeutics
Hemodynamics
Pediatrics
Survival

Keywords

  • Africa
  • Dexamethasone
  • sepsis syndrome
  • septic shock (pediatric)

Cite this

Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis. / Slusher, Tina; Gbadero, Daniel; Howard, Cynthia; Lewison, Laura; Giroir, Brett; Toro, Luis; Levin, Daniel; Holt, Elizabeth; Mccracken, George H.

In: Pediatric Infectious Disease Journal, Vol. 15, No. 7, 01.07.1996, p. 579-583.

Research output: Contribution to journalArticle

Slusher, Tina ; Gbadero, Daniel ; Howard, Cynthia ; Lewison, Laura ; Giroir, Brett ; Toro, Luis ; Levin, Daniel ; Holt, Elizabeth ; Mccracken, George H. / Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis. In: Pediatric Infectious Disease Journal. 1996 ; Vol. 15, No. 7. pp. 579-583.
@article{0b7da96c66f445439556874bc92106c2,
title = "Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis",
abstract = "Objective. To determine the effect of moderate dose dexamethasone administered before antibiotics on the outcome of African children with sepsis. Methods. The design was a randomized, double blinded, placebo- controlled trial of dexamethasone (0.2 mg/kg) vs. placebo given intravenously before antibiotic therapy. Patients were recruited from the patient populations at two missionary hospitals. Primary outcome variables were determined before analysis of data. Results. Seventy-two children with sepsis were enrolled in the study. Treatment with dexamethasone was not associated with improved outcome for any six outcome variables: survival to discharge (83{\%}, dexamethasone group; 89{\%}, placebo group); hemodynamic stability at 48 h (33{\%}, dexamethasone group; 49{\%}, placebo group); median length of hospital stay (11 days, dexamethasone group; 11 days, placebo group); normal at discharge (90{\%}, dexamethasone group; 75{\%}, placebo group); normal at follow- up (90{\%}, dexamethasone group; 72{\%}, placebo group); and afebrile at 48 to 72 h(61{\%}, dexamethasone group; 44{\%}, placebo group). Conclusions. These data indicate that a moderate dose of dexamethasone given before antibiotic therapy did not improve outcome in the pediatric patients with sepsis whom we studied.",
keywords = "Africa, Dexamethasone, sepsis syndrome, septic shock (pediatric)",
author = "Tina Slusher and Daniel Gbadero and Cynthia Howard and Laura Lewison and Brett Giroir and Luis Toro and Daniel Levin and Elizabeth Holt and Mccracken, {George H.}",
year = "1996",
month = "7",
day = "1",
doi = "10.1097/00006454-199607000-00004",
language = "English (US)",
volume = "15",
pages = "579--583",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis

AU - Slusher, Tina

AU - Gbadero, Daniel

AU - Howard, Cynthia

AU - Lewison, Laura

AU - Giroir, Brett

AU - Toro, Luis

AU - Levin, Daniel

AU - Holt, Elizabeth

AU - Mccracken, George H.

PY - 1996/7/1

Y1 - 1996/7/1

N2 - Objective. To determine the effect of moderate dose dexamethasone administered before antibiotics on the outcome of African children with sepsis. Methods. The design was a randomized, double blinded, placebo- controlled trial of dexamethasone (0.2 mg/kg) vs. placebo given intravenously before antibiotic therapy. Patients were recruited from the patient populations at two missionary hospitals. Primary outcome variables were determined before analysis of data. Results. Seventy-two children with sepsis were enrolled in the study. Treatment with dexamethasone was not associated with improved outcome for any six outcome variables: survival to discharge (83%, dexamethasone group; 89%, placebo group); hemodynamic stability at 48 h (33%, dexamethasone group; 49%, placebo group); median length of hospital stay (11 days, dexamethasone group; 11 days, placebo group); normal at discharge (90%, dexamethasone group; 75%, placebo group); normal at follow- up (90%, dexamethasone group; 72%, placebo group); and afebrile at 48 to 72 h(61%, dexamethasone group; 44%, placebo group). Conclusions. These data indicate that a moderate dose of dexamethasone given before antibiotic therapy did not improve outcome in the pediatric patients with sepsis whom we studied.

AB - Objective. To determine the effect of moderate dose dexamethasone administered before antibiotics on the outcome of African children with sepsis. Methods. The design was a randomized, double blinded, placebo- controlled trial of dexamethasone (0.2 mg/kg) vs. placebo given intravenously before antibiotic therapy. Patients were recruited from the patient populations at two missionary hospitals. Primary outcome variables were determined before analysis of data. Results. Seventy-two children with sepsis were enrolled in the study. Treatment with dexamethasone was not associated with improved outcome for any six outcome variables: survival to discharge (83%, dexamethasone group; 89%, placebo group); hemodynamic stability at 48 h (33%, dexamethasone group; 49%, placebo group); median length of hospital stay (11 days, dexamethasone group; 11 days, placebo group); normal at discharge (90%, dexamethasone group; 75%, placebo group); normal at follow- up (90%, dexamethasone group; 72%, placebo group); and afebrile at 48 to 72 h(61%, dexamethasone group; 44%, placebo group). Conclusions. These data indicate that a moderate dose of dexamethasone given before antibiotic therapy did not improve outcome in the pediatric patients with sepsis whom we studied.

KW - Africa

KW - Dexamethasone

KW - sepsis syndrome

KW - septic shock (pediatric)

UR - http://www.scopus.com/inward/record.url?scp=0029986186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029986186&partnerID=8YFLogxK

U2 - 10.1097/00006454-199607000-00004

DO - 10.1097/00006454-199607000-00004

M3 - Article

C2 - 8823850

AN - SCOPUS:0029986186

VL - 15

SP - 579

EP - 583

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 7

ER -